注射用头孢哌酮钠他唑巴坦钠配伍禁忌临床分析  

Clinical Analysis of Incompatibility of Cefoperazone Sodium and Tazobactam Sodium for Injection

作　　者：程英 段菲 权晨 CHENG Ying;DUAN Fei;QUAN Chen(Yingshan People' 5 Hospital, Huanggang, Hubei, China 438799;Huanggang Central Hospital, Huanggang, Hubei, China 438000)

机构地区：[1]湖北省英山县人民医院,湖北黄冈438799 [2]湖北省黄冈市中心医院,湖北黄冈438000

出　　处：《中国药业》2019年第3期73-75,共3页China Pharmaceuticals

基　　金：湖北省自然科学基金[2016CBD0374]

摘　　要：目的探讨注射用头孢哌酮钠他唑巴坦钠与不同药物的配伍禁忌。方法回顾性分析医院2015年2月至2017年8月注射用头孢哌酮钠他唑巴坦钠联用其他药物后发生不良反应的142例患者的临床资料,收集患者性别、年龄、病情、联合用药、不良反应等情况,并进行分析。结果注射用头孢哌酮钠他唑巴坦钠联合用药不良反应发生率在性别组成上无差异(P> 0. 05),18岁以下及60岁以上不良反应发生率高于19～59岁人群;该药联合呼吸系统及消化系统药不良反应发生例数较多,其中联合左氧氟沙星发生不良反应最多,其次为莫西沙星。不良反应主要累及皮肤及其附件(49. 30%),临床表现以皮疹和瘙痒者居多;其次,累及消化系统(29. 58%),临床表现以菌群失调、腹泻、腹胀为主。结论老年人及青少年应用头孢哌酮钠他唑巴坦钠时应注意配伍方式,临床可减少其与呼吸系统、消化系统药物的联用,特别是与左氧氟沙星、莫西沙星等抗菌药物联用时,应时刻观察患者体征及反应,提高临床用药安全性。Objective To investigate the incompatibility of Cefoperazone Sodium and Tazobactam Sodium for Injection with different drugs. Methods A retrospective analysis was performed in the clinical data of 142 patients with adverse drug reactions after treatment of Cefoperazone Sodium and Tazobactam Sodium for Injection combined with different drugs in the hospital from February 2015 to August 2017. The related clinical data of patients,such as gender,age,condition,the combined use of drugs and types of adverse reactions were collected for statistical analysis. Results There was no difference in the incidence rate of adverse drug reactions caused by Cefopera zone Sodium and Tazobactam Sodium for Injection combined with other drugs between different gender( P > 0. 05). The incidence rate of adverse drug reactions in the people under 18 years old and over 60 years old was higher than that in the people aged19-59 years old. There were many cases with adverse drug reactions caused by Cefoperazone Sodium and Tazobactam Sodium for Injection combined with respiratory system drugs and digestive system drugs. Among them, the patients with adverse drug reactions caused by combination with levofloxacin were the most, followed by moxifloxacin. The adverse drug reactions mainly occurred in the skin and its appendages( 49. 30%), the clinical manifestations mainly were rash and pruritus, followed by the digestive system( 29. 58%), and the clinical manifestations mainly were dysbacteria,diarrhea,and abdominal distention. Conclusion The compatibility of Cefoperazone Sodium and Tazobactam Sodium for Injection for the elderly and young people should be paid attention to. In clinical practice,its combined use of the respiratory system and the digestive system drugs should be reduced,especially with levofloxacin,moxifloxacin and other antibiotics,the patients’ physical signs and reactions should be observed at all times to improve the safety of the clinical medication.

关 键 词：注射用头孢哌酮钠他唑巴坦钠 配伍禁忌 药品不良反应 合理用药 

分 类 号：R969.3[医药卫生—药理学] R978.1[医药卫生—药学]